PMID- 31925433
OWN - NLM
STAT- MEDLINE
DCOM- 20210520
LR  - 20210520
IS  - 1943-7730 (Electronic)
IS  - 0007-5027 (Linking)
VI  - 51
IP  - 5
DP  - 2020 Sep 1
TI  - Severe Platelet Transfusion Refractoriness in Association with Antibodies Against 
      CD36.
PG  - 540-544
LID - 10.1093/labmed/lmz091 [doi]
AB  - Platelet-transfusion refractoriness (PTR) is common in patients with 
      hematological malignancies. The etiology of immune PTR is typically human 
      leukocyte antigen (HLA) antibodies (Abs) from pregnancy or previous transfusion. 
      Herein, we report PTR in the setting of induction chemotherapy for acute 
      myelogenous leukemia (AML) from Abs against CD36/glycoprotein (GP)IV. A 
      66-year-old African American woman presented with anemia and thrombocytopenia. 
      She was found to have transfusion-dependent AML, and a 7 + 3 regimen (7 days of 
      standard-dose cytarabine and 3 days of an anthracycline antibiotic or an 
      anthracenedione, most often daunorubicin) was initiated. The patient developed 
      profound thrombocytopenia, with platelet nadir of 0 by day 13. The results of HLA 
      antibody screening were negative. However, the results of a screening test for 
      platelet-specific antibodies screen showed Abs against cluster of differentiation 
      (CD)36. The platelets of the patient lacked expression of CD36, and DNA analysis 
      showed mutations in the CD36 gene. HLA Ab-mediated PTR is common in patients with 
      hematological malignancies. However, once HLA Abs are excluded, other 
      less-frequent Abs should be considered, particularly in patient populations of 
      Asian, African, or Middle Eastern descent.
CI  - (c) American Society for Clinical Pathology 2020. All rights reserved. For 
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Schmidt, Amy E
AU  - Schmidt AE
AD  - Department of Pathology and Laboratory Medicine, University of Rochester Medical 
      Center, Rochester, New York.
FAU - Sahai, Tanmay
AU  - Sahai T
AD  - Department of Pathology and Laboratory Medicine, University of Rochester Medical 
      Center, Rochester, New York.
AD  - Department of Hematology and Oncology, Lenox Hill Hospital, New York, New York.
FAU - Refaai, Majed A
AU  - Refaai MA
AD  - Department of Pathology and Laboratory Medicine, University of Rochester Medical 
      Center, Rochester, New York.
FAU - Sullivan, Mia
AU  - Sullivan M
AD  - The Platelet & Neutrophil Immunology Laboratory, Blood Center of Wisconsin (part 
      of Versiti), Milwaukee, WI.
FAU - Curtis, Brian R
AU  - Curtis BR
AD  - The Platelet & Neutrophil Immunology Laboratory, Blood Center of Wisconsin (part 
      of Versiti), Milwaukee, WI.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Lab Med
JT  - Laboratory medicine
JID - 0250641
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 776B62CQ27 (Decitabine)
RN  - Platelet Glycoprotein IV Deficiency
SB  - IM
MH  - Aged
MH  - Antimetabolites, Antineoplastic/*administration & dosage
MH  - Blood Platelet Disorders/complications/genetics/*immunology
MH  - Decitabine/*administration & dosage
MH  - Fatal Outcome
MH  - Female
MH  - Genetic Diseases, Inborn/complications/genetics/*immunology
MH  - Humans
MH  - Induction Chemotherapy
MH  - Leukemia, Myeloid, Acute/blood/*drug therapy
MH  - *Platelet Transfusion
OTO - NOTNLM
OT  - CD36
OT  - human platelet antigen
OT  - isoimmunization
OT  - platelet
OT  - platelet antibody
OT  - transfusion refractoriness
EDAT- 2020/01/12 06:00
MHDA- 2021/05/21 06:00
CRDT- 2020/01/12 06:00
PHST- 2020/01/12 06:00 [pubmed]
PHST- 2021/05/21 06:00 [medline]
PHST- 2020/01/12 06:00 [entrez]
AID - 5700528 [pii]
AID - 10.1093/labmed/lmz091 [doi]
PST - ppublish
SO  - Lab Med. 2020 Sep 1;51(5):540-544. doi: 10.1093/labmed/lmz091.